Frequency Electronics reported earnings of 34 cents per share for the fourth quarter, up from 28 cents per share in the ...

Astellas Pharma recently announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a regenerative therapy to treat hearing loss.

Frequency Therapeutics Inc (NASDAQ:FREQ) has completed its merger with Korro Bio, Inc. The company has also announced a private placement of $117 million. Post-merger, the combined company is ...

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple ...

Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.

Korro Bio Inc and Frequency Therapeutics Inc FREQ announced an all- stock merger transaction. Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of ...

Frequency Therapeutics announced it will scrap development of a drug called FX-322 after testing failed to show improvement in speech perception in people with noise-induced sensorineural hearing ...

Frequency Therapeutics said its hearing loss drug candidate failed to beat a placebo in its second mid-stage clinical trial. The biotech is now focusing its regenerative medicine platform on the ...

Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs Emma Betuel 7:19 AM PST · November 9, 2021 ...

Frequency Therapeutics, Inc. (FREQ) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.16 per share a year ago ...